As a patient considering PRLT at Bad Berka, you need to know that there are two essential inclusion criteria that are recommended by the German Society of Nuclear Medicine:
1) Distant metastases with high PSMA expression as confirmed on pre-therapy Ga-68-PSMA-PET/CT and
2) progressive disease despite extensive previous treatments.
There are other considerations too. Please see risks in the section on PRLT Risks.